Xenetic Biosciences, Inc. (XBIO)
XBIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.80
-0.0732 (-3.91%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $4.29m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.58 to $4.94
- Average volume
- 85.3k
- Previous close
- $1.87
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.03m | $766.0k | $807.0k | $661.0k |
| Gross profit | $1.03m | $766.0k | $807.0k | $661.0k |
| Operating income | -$545.0k | -$623.0k | -$502.0k | -$972.0k |
| Net income | -$510.0k | -$579.0k | -$456.0k | -$930.0k |
Last four quarters: revenue $3.26m, margin -75.9%, free cash flow –
News
6 latest- Xenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused Pipeline RTTNews · Sep 17, 2026
- Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue EstimatesZacks · Oct 30, 2025
- Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesZacks · Aug 12, 2025
- USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass EstimatesZacks · Apr 22, 2025
- XENETIC BIOSCIENCES Earnings Preview: Recent $XBIO Insider Trading, Hedge Fund Activity, and MoreQuiver Quantitative · Mar 17, 2025
- ElectroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue EstimatesZacks · Aug 7, 2024
The company
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- xeneticbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.